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The management of urinary tract infection (UTI) in individuals with spinal cord injury (SCI) continues to be of concern, due
to complications that can occur. An emerging concept that is a common underlying pathophysiological process is involved,
wherein pathogens causing UTI have a role in inﬂammatory progression. We hypothesized that members of the commensal ﬂora,
such as lactobacilli, may counter this reaction through anti-inﬂammatory mediation. This was assessed in a pilot two-patient
study in which probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri were administered to one patient and placebo to
another, both along with antibiotics to treat acute UTI. Urinary TNF-alpha was signiﬁcantly downregulated (P = .015) in the
patient who received the probiotic and who used intermittent catheterization compared with patient on placebo and using an
indwelling catheter. The extent to which this alteration resulted in improved well-being in spinal cord injured patients remains to
be determined in a larger study.
Copyright © 2009 Kingsley C. Anukam et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Chronic urinary tract infection (UTI) and bladder car-
cinoma remain prominent complications and causes of
morbidity and mortality following spinal cord injury (SCI)
[1–3]. An emerging concept is that there is a common
underlying pathophysiological process involved, wherein
pathogens causing chronic UTI induce inﬂammation and
other eﬀects, for example which increase the risk of bladder
cancer [3]. Chronic UTI leads to earlier mortality and
although the mechanisms are unclear, the production of
carcinogens and inﬂammatory factors in the bladder has the
potential to cause cancer at local and distant tissue sites.
Innovative ways to modulate inﬂammatory processes
are needed, as current neurogenic bladder management
relies almost totally on antibiotic use, and this is essentially
ineﬀective in eradicating multidrug resistant bacteria in
dense bioﬁlms. Previous studies have shown that probiotic
bacteria have the potential to interfere with infectious and
inﬂammatory processes, including in the urogenital tract [4–
7]. The oral intake of probiotic strains Lactobacillus rham-
nosus GR-1 with Lactobacillus reuteri (formerly fermentum)
RC-14 has been shown to reduce the pathogen load in the
urogenital tract [7], and a recent study using a L. acidophilus
strain showed equal eﬃcacy to prophylactic antibiotics in
preventing recurrent UTI in children [8].
Direct instillation of lactobacilli into the bladder of
patients with neurogenic disease has been attempted without
success, with the lactobacilli being not able to colonize the
bladder [9]. An avirulent E. coli strain has been implanted
into the bladder of SCI patients and shown to reduce the
ability of infectious organisms to colonize [10]. A study
showing that probiotic lactobacilli can be given with antibi-
otics to cure acute infection [7], and oral administration2 Advances in Urology
of lactobacilli can mediate analgesic functions in the gut
[11] formed a basis for the present protocol. In addition,
the reported anti-inﬂammatory properties of L. rhamnosus
GR-1 and L. reuteri RC-14 [12] made it possible to explore
their eﬀect on inﬂammation in SCI patients. As a proof-of
principlestudy,twoSCIpatientswithUTIwereadministered
antibiotics plus lactobacilli or placebo.
2. PatientDetailsand ExperimentalMethods
2.1. Patient Recruitment. T h es u b j e c t sw e r er e c r u i t e df r o m
the outpatient population and “alumni” of the Regional
SCI Rehabilitation Programs in London, Ontario (Parkwood
Hospital/St Joseph’s Health Care).
2.2. Study Procedures. After obtaining signed informed con-
sent (Day 0), a blood sample was collected for cytokine, liver
andkidneymarkeranalysis,andaurinesamplewascollected
to conﬁrm infection and to examine cytokine levels. The
subjects were treated with antibiotics (as detailed below),
randomized to receive the probiotics/placebo capsules and
instructedonhowandwhentotakeeach(twocapsulestaken
1hourafterdoseofantibiotic).Bothsubjectscameforvisit2,
(midway through antibiotic treatment), visit 3 (at the end of
antibiotic treatment), visit 4 (day 30) and visit 5 (day 90). At
thesevisits,theCoordinator/Nursecollectedbloodandurine
samples for cytokines analysis.
2.3. Method for Analyzing Urine and Serum Cytokines—
Biomultiplex Panels (Premixed Assays). Cytokine concentra-
tions from urine and serum were analyzed using ﬂuorescent
microsphere-based multiplexing technology with Bio-Plex
200 analyzer (Bio-Rad, Inc., Calif, USA). Cytokines, inter-
leukin (IL)-6, IL-8, IL-10, IL-12(p70), and tumor necrosis
factor (TNF)-α were analyzed using a premixed multiplex
panel (Bio-Rad, San Diego, CA). All determinations were
performed in duplicate wells and concentrations calculated
by the Bio-Plex Manager software, using the standard curves
derived from the recombinant cytokine standards.
2.4. Patient 1. A 31-year-old female sustained a com-
plete spinal cord injury with ASIA score of S4–S5 on
the 13 May, 2003. She has urinary incontinence and no
urethral sensation. She has a history of recurrent UTI,
each treated with antibiotics. She reported no pain in
her bladder or kidney, and uses an indwelling catheter
to manage micturition. She visited her physician at Park-
wood hospital on 11 October, 2007, for a suspected
UTI. Her urine sample was slightly cloudy, positive for
nitrite, and moderate for leukocyte esterase. The culture
yielded Citrobacter freundii (> 100 × 106 cfu/L) and
Enterococcus spp (10–100 × 106 cfu/L). The Citrobacter fre-
undiiwas susceptible to Cefotaxime, Ciproﬂoxacin, Gen-
tamicin, Imipenem, Pipercillin/Tazobactam, Tobramycin,
and Trimethoprim/Sulfamethoxazole. Enterococcus spp was
susceptible to Ampicillin, Ciproﬂoxacin, and Nitrofuran-
toin. On screening for inclusion in the study, the subject
weighed 63.6kg, had a blood pressure of (Systolic/Diastolic)
96/72mmHg, sitting pulse rate of 80beats/minute, and her
means of mobility was a wheelchair. She was prescribed oral
Ciproﬂoxacin (500mg × 2) daily for 12 days and the study
product (two capsules daily for 90 days).
2.5. Patient 2. A 45-year-old male with a medical history
of incomplete spinal cord injury in 1999 with ASIA score
of muscle grade <3h a dm o r et h a n2 4t r e a t e de p i s o d e s
of UTI since then (treated with Norﬂoxacin, Amoxycillin,
Ciproﬂoxacin, Cotrimoxazole, Macrobid, Cefexime). His
last antibiotic treatment for a UTI was on 29 October,
2007. On 22 November 2007, he had signs and symptoms
synonymous with UTI and decided to take his urine sample
to the laboratory for culture and sensitivity. The subject
had heard about the probiotic study, and traveled with his
caregiver more than 293 kilometers to the study center at
Parkwood hospital, London, Ontario, where he was screened
and enrolled on 29th November, 2007. The subject used a
wheelchair and at enrolment weighed 95.6kg, with a blood
pressure of 120/72mmHg, sitting pulse of 89beats/minute,
respiration of 18breaths/minute and a body temperature
of 37.3◦C. He used intermittent catheterization for bladder
management. He provided a urine sample (30mls) for
urinalysis (dipstick) and cytokine assessment. A blood
sample (10mls) was collected for serum cytokines. The
urinalysis result showed presence of moderate leucocytes,
positive nitrite, cloudy a strong urine odor, and Escherichia
coli (>100×106 cfu/L), sensitive to Cephalothin, Gentamicin,
Ciproﬂoxacin, Cotrimoxazole, Ceﬁxime, Ampicillin, and
Nitrofurantoin. The subject was prescribed Nitrofurantoin
100mg for 14 days and randomized to receive 2 capsules of
probiotic lactobacilli daily for 90 days.
2.6. Statistical Analysis. Mann-Whitney U test was used
when comparing the means of continuous data between two
independent groups. Two-sided Fisher’s Exact Test was used
for signiﬁcant associations between two categorical variables
in 2 by 2 contingency tables. Diﬀerences were considered
statistically signiﬁcant if P-value was <.05.
2.7. Ethics Review Board. The ethics review board of the
University of Western Ontario and Health Canada gave
approval for this study.
3. Results
Urine and serum cytokine results for patient 1 (Placebo)
and patient 2 (Probiotics) for Visit no. 1 (day 0) to visit no.
5 (day 90) are shown in Figure 1. At baseline (day 0) the
cytokine value was taken as a ratio, and subsequent visits
were calculated as a ratio to the baseline cytokine value.
The cytokines from patient 2 were downregulated com-
pared initial baseline presentation with UTI. For example
his IL-8 baseline value was 545.63pg/mL at inclusion,
downregulated to 36.74pg/mL at day 7 amounting to 93.3%
reduction,comparedtoa56.9%reductioninpatient1.There
was a slight increase in urinary cytokines for patient 2 atAdvances in Urology 3
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Figure 1: Comparative urine and serum cytokines from patient 1 and patient 2. Serum and urine samples were collected from the patients at
days 0, 7, 14, 30 and 90. Interleukins (IL)-6, IL-8, IL-10, IL-12(p70), and tumor necrosis factor (TNF)-α were analyzed using a premixed
multiplex panel and concentrations calculated by the Bio-Plex Manager software. Diﬀerences were considered statistically signiﬁcant if P-
value was <.05.
day 30 but the values especially IL-6, IL-8, IL-12 and TNF-
alpha did not go above the baseline values obtained ab initio
when he had UTI. The urinary cytokine level for IL-6 was
0.508pg/mL on day 14 compared to 1.581pg/mL for the
placebo patient 1, and 0.223pg/mL on day 90 compared to
1.58pg/mL.
For urinary IL-8, there was downregulation in patient 2
in all sample days (0.067pg/mL, 0.607pg/mL, 0.941pg/mL,
and 0.228pg/mL) compared to patient 1 (0.432pg/mL,
2.375pg/mL, 2.556pg/mL, and 0.662pg/mL) (P = .15). The
serum IL-8 had a similar trend with a signiﬁcant diﬀerence
(P = .05) between patients 1 and 2.
Urinary TNF-alpha was signiﬁcantly downregulated in
patient 2 (P = .015) on all the days sampled, com-
pared with patient 1: patient 2 had TNF-alpha on day 7
(0.08pg/mL), day 14 (0.13pg/mL), day 30 (0.52pg/mL)
and 90 (0.106pg/mL), while patient 1 had 0.68pg/mL,
3.01pg/mL, 1.75pg/mL, and 1.18pg/mL. For serum TNF-
alpha, there was no signiﬁcant diﬀerence (P = .055) between
the two patients.
Patient 2 had urinary and serum IL-10 regulated but this
was not statistically diﬀerent from patient 1 (P = .055 for
urine and P = .309 for serum. Urinary IL-12 (p70) was also
downregulated in patient 2 on all sampling days compared
to patient 1 (0.552pg/mL versus 0.808pg/mL, 0.884pg/mL
versus 1.808pg/mL, 0.884pg/mL versus 1.178pg/mL, and
0.552pg/mL versus 0.84pg/mL) (P = .20). Serum IL-12
(p70) was not detected in either patient.
4. Discussion
This is the ﬁrst study showing the eﬀect of probiotics
in augmenting antimicrobial therapy in downregulation of
inﬂammatory urinary cytokines in a spinal cord injured4 Advances in Urology
individual with UTI. Downregulation of proinﬂammatory
cytokines, especially IL-6, IL-8 and TNF-alpha, in the
patient who took probiotics is important as these cytokines
contribute to an immune-mediated impairment of axonal
conduction [13, 14]. TNF-α is also strongly implicated in
neuropathic pain. It induces axonal damage, macrophage
recruitment, and ectopic activity in peripheral nerve ﬁbers
[15].
In men, UTI is invariable due to urethral catheter
ascension of pathogens [16]. In females, lactobacilli therapy
leads to the probiotic organisms reaching the vagina and
potentially the urethra via natural ascension along the
perineal skin. However, this would not occur in males.
Thus, physical competitive exclusion of the uropathogens
is unlikely the mechanism of any positive anti-infective
eﬀects of the lactobacilli. However, lactobacilli can modulate
mucosal immunity in the gut and even apparently reduce
the risk of bladder cancer recurrence via this pathway
[4]. In patient 2, anti-inﬂammatory eﬀects were noted
in the serum as well as the urine thereby potentially
supporting this mechanistic route. In acute UTI, IL-6
and TNF-alpha are particularly associated with symptoma-
tology [17, 18], and the ability of probiotic lactobacilli
to downregulate these cytokines could have implications
for better managing UTI in SCI as well as non-SCI
patients.
A previous study found that consumption of products
containing L. gasseri CECT 5714 and L. coryniformisCECT
5711 induced an increase in the proportion of serum natural
killer (NK) cells and in IgA concentrations [19], providing
additional precedent for our ﬁndings.
IL-12 (p70) was only detected in the urine of patients
with lower values observed in the probiotics patient. It is
noteworthy that human Interleukin-12 (p70), also known
as natural killer cell stimulatory factor (NKSF) or cytotoxic
lymphocyte maturation factor (CLMF), is a potent regulator
of cell-mediated immune responses. IL-12 also promotes the
development of proinﬂammatory-Th1-like CD4+ cells and
cytotoxicCD8+TcellsanditinducesNKandTcellstosecrete
large amounts of the proinﬂammatory cytokine [20].
It could be argued that the pathogenesis of gender-
related diﬀerences in the rate of infectious diseases may
have played a role between the two patients but interestingly
under physiological conditions, the previous studies have
shown no signiﬁcant gender-related diﬀerence in the level of
urinecytokinesespeciallyIL-6,IL-10,TNF-alpha[21].Urine
proinﬂammatory cytokines IL-6 and IL-8 have been found
to be signiﬁcantly higher in male patients with bacteriuria
than in males without bacteriuria. It is also possible that
patient 1 with an indwelling catheter presents a diﬀerent
inﬂammatory scenario than patient 2 who used intermittent
catheterization. Such factors should be explored when a
larger study is designed.
In summary, this two-case study provided valuable
insight into how probiotic lactobacilli could be tested to
determine if they provide adjunct beneﬁts in the manage-
ment of UTI in SCI patients. The preliminary evidence of
immunemodulationinamalepatientalsosuggeststhatsuch
therapy could have applicability to the care of males with
UTI, a ﬁnding that has not been explored in the previous
probiotic studies.
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